Diasorin SpASTU:34D +3.02%74 Interest Coverage is 13.02 as of Dec. 2025, which is 60% below its 10-year median of 32.80. GuruFocus rates STU:34D with a GF Score™ of 74/100 and a GF Value™ of €90.44 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 94 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 54.26% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Diasorin SpA's
Operating Income
for the
three
months ended in Dec. 2025 was €65 Mil. Diasorin SpA's Interest Expense for the
three
months ended in Dec. 2025 was €-5 Mil.
Diasorin SpA's interest coverage for the quarter that ended in Dec. 2025 was 13.02.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Diasorin SpA's Interest Coverage or its related term are showing as below:
STU:34D'
s Interest Coverage Range Over the Past 10 Years
Min: 8.11 Med: 32.8 Max: 97.67
Current: 13.57
STU:34D's Interest Coverage is ranked better than 54.26% of 94
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.155
vs STU:34D: 13.57
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Diasorin SpA Interest Coverage Related Terms
Diasorin SpA Interest Coverage Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
STU:34D vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA (STU:34D) has a Interest Coverage of 13.02 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Diasorin SpA and its competitors. This is 60% below median its historical median of 32.80. Over the past decade, Diasorin SpA's Interest Coverage has ranged from 8.11 to 97.67. According to the industry distribution chart, Diasorin SpA ranks #43 out of 94 companies in the Medical Diagnostics & Research industry, placing it in the top 45.7%.
Is Diasorin SpA's Interest Coverage too high?
Diasorin SpA's current Interest Coverage of 13.02 is 60% below median its 10-year median of 32.80. Over the past 10 years, this metric has ranged from a low of 8.11 to a high of 97.67. The Medical Diagnostics & Research industry median Interest Coverage is 9.16. Diasorin SpA's value of 13.02 is 42.2% above this industry median. Based on the distribution chart, Diasorin SpA ranks #43 out of 94 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #43 out of 94 companies for Interest Coverage. This puts Diasorin SpA in the upper half of its industry. The industry median Interest Coverage is 9.16. Diasorin SpA's value of 13.02 is 42.2% above this benchmark. Historically, Diasorin SpA's own Interest Coverage has ranged from 8.11 to 97.67 over the past decade. While the company's 10-year median is 32.80 vs. the industry median of 9.16, Diasorin SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.16, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diasorin SpA's current Interest Coverage of 13.02 is 42.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Diasorin SpA and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current Interest Coverage is 13.02, which is 60% below median its own 10-year median of 32.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (STU:34D) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.44, compared to a current price of €70.24 — trading 22.3% below its estimated fair value. The current Interest Coverage is 13.02, which is 60% below median its 10-year median of 32.80 and 42.2% above the Medical Diagnostics & Research industry median of 9.16. Diasorin SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Diasorin SpA (STU:34D), the current Interest Coverage is 13.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (STU:34D) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €70.24 is trading 22.3% below its estimated GF Value™ of €90.44.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for STU:34D:
Interest Coverage: 13.02 (60% below median its 10-year median of 32.80)
GF Value™: €90.44 vs. price of €70.24 (22.3% below fair value)
Industry Position: 42.2% above the Medical Diagnostics & Research median (#43 of 94)
No single metric tells the full story. See the STU:34D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
74GF Score
Get the complete analysis for STU:34D
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:34D has been successfully added to your 
